Automatically generated by Mendeley Desktop 1.17.11
Any changes to this file will be lost if it is regenerated by Mendeley.

BibTeX export options can be customized via Preferences -> BibTeX in Mendeley Desktop

@article{Northcott2012b,
abstract = {Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas. SCNAs are common in medulloblastoma, and are predominantly subgroup-enriched. The most common region of focal copy number gain is a tandem duplication of SNCAIP, a gene associated with Parkinson's disease, which is exquisitely restricted to Group 4$\alpha$. Recurrent translocations of PVT1, including PVT1-MYC and PVT1-NDRG1, that arise through chromothripsis are restricted to Group 3. Numerous targetable SCNAs, including recurrent events targeting TGF-$\beta$ signalling in Group 3, and NF-$\kappa$B signalling in Group 4, suggest future avenues for rational, targeted therapy.},
author = {Northcott, Paul a and Shih, David J H and Peacock, John and Garzia, Livia and Morrissy, a Sorana and Zichner, Thomas and St{\"{u}}tz, Adrian M and Korshunov, Andrey and Reimand, J{\"{u}}ri and Schumacher, Steven E and Beroukhim, Rameen and Ellison, David W and Marshall, Christian R and Lionel, Anath C and Mack, Stephen and Dubuc, Adrian and Yao, Yuan and Ramaswamy, Vijay and Luu, Betty and Rolider, Adi and Cavalli, Florence M G and Wang, Xin and Remke, Marc and Wu, Xiaochong and Chiu, Readman Y B and Chu, Andy and Chuah, Eric and Corbett, Richard D and Hoad, Gemma R and Jackman, Shaun D and Li, Yisu and Lo, Allan and Mungall, Karen L and Nip, Ka Ming and Qian, Jenny Q and Raymond, Anthony G J and Thiessen, Nina T and Varhol, Richard J and Birol, Inanc and Moore, Richard a and Mungall, Andrew J and Holt, Robert and Kawauchi, Daisuke and Roussel, Martine F and Kool, Marcel and Jones, David T W and Witt, Hendrick and Fernandez-L, Africa and Kenney, Anna M and Wechsler-Reya, Robert J and Dirks, Peter and Aviv, Tzvi and Grajkowska, Wieslawa a and Perek-Polnik, Marta and Haberler, Christine C and Delattre, Olivier and Reynaud, St{\'{e}}phanie S and Doz, Fran{\c{c}}ois F and Pernet-Fattet, Sarah S and Cho, Byung-Kyu and Kim, Seung-Ki and Wang, Kyu-Chang and Scheurlen, Wolfram and Eberhart, Charles G and F{\`{e}}vre-Montange, Michelle and Jouvet, Anne and Pollack, Ian F and Fan, Xing and Muraszko, Karin M and Gillespie, G Yancey and {Di Rocco}, Concezio and Massimi, Luca and Michiels, Erna M C and Kloosterhof, Nanne K and French, Pim J and Kros, Johan M and Olson, James M and Ellenbogen, Richard G and Zitterbart, Karel and Kren, Leos and Thompson, Reid C and Cooper, Michael K and Lach, Boleslaw and McLendon, Roger E and Bigner, Darell D and Fontebasso, Adam and Albrecht, Steffen and Jabado, Nada and Lindsey, Janet C and Bailey, Simon and Gupta, Nalin and Weiss, William a and Bogn{\'{a}}r, L{\'{a}}szl{\'{o}} and Klekner, Almos and {Van Meter}, Timothy E and Kumabe, Toshihiro and Tominaga, Teiji and Elbabaa, Samer K and Leonard, Jeffrey R and Rubin, Joshua B and Liau, Linda M and {Van Meir}, Erwin G and Fouladi, Maryam and Nakamura, Hideo and Cinalli, Giuseppe and Garami, Mikl{\'{o}}s and Hauser, Peter and Saad, Ali G and Iolascon, Achille and Jung, Shin and Carlotti, Carlos G and Vibhakar, Rajeev and Ra, Young Shin and Robinson, Shenandoah and Zollo, Massimo and Faria, Claudia C and Chan, Jennifer a and Levy, Michael L and Sorensen, Poul H B and Meyerson, Matthew and Pomeroy, Scott L and Cho, Yoon-Jae and Bader, Gary D and Tabori, Uri and Hawkins, Cynthia E and Bouffet, Eric and Scherer, Stephen W and Rutka, James T and Malkin, David and Clifford, Steven C and Jones, Steven J M and Korbel, Jan O and Pfister, Stefan M and Marra, Marco a and Taylor, Michael D},
doi = {10.1038/nature11327},
file = {:Users/evayap/Library/Application Support/Mendeley Desktop/Downloaded/Northcott et al. - 2012 - Subgroup-specific structural variation across 1,000 medulloblastoma genomes.pdf:pdf},
issn = {1476-4687},
journal = {Nature},
keywords = {Carrier Proteins,Carrier Proteins: genetics,Cerebellar Neoplasms,Cerebellar Neoplasms: classification,Cerebellar Neoplasms: genetics,Cerebellar Neoplasms: metabolism,Child,DNA Copy Number Variations,DNA Copy Number Variations: genetics,Gene Duplication,Gene Duplication: genetics,Genes, myc,Genes, myc: genetics,Genome, Human,Genome, Human: genetics,Genomic Structural Variation,Genomic Structural Variation: genetics,Genomics,Hedgehog Proteins,Hedgehog Proteins: metabolism,Humans,Medulloblastoma,Medulloblastoma: classification,Medulloblastoma: genetics,Medulloblastoma: metabolism,NF-kappa B,NF-kappa B: metabolism,Nerve Tissue Proteins,Nerve Tissue Proteins: genetics,Oncogene Proteins, Fusion,Oncogene Proteins, Fusion: genetics,Proteins,Proteins: genetics,RNA, Long Noncoding,Signal Transduction,Transforming Growth Factor beta,Transforming Growth Factor beta: metabolism,Translocation, Genetic,Translocation, Genetic: genetics},
month = {aug},
number = {7409},
pages = {49--56},
pmid = {22832581},
publisher = {Nature Publishing Group},
title = {{Subgroup-specific structural variation across 1,000 medulloblastoma genomes.}},
url = {http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3683624{\&}tool=pmcentrez{\&}rendertype=abstract},
volume = {488},
year = {2012}
}
@article{Seguin2015b,
author = {Seguin, Laetitia and Desgrosellier, Jay S. and Weis, Sara M. and Cheresh, David a.},
doi = {10.1016/j.tcb.2014.12.006},
file = {:Users/evayap/Library/Application Support/Mendeley Desktop/Downloaded/Seguin et al. - 2015 - Integrins and cancer regulators of cancer stemness, metastasis, and drug resistance.pdf:pdf},
issn = {09628924},
journal = {Trends in Cell Biology},
keywords = {cancer,drug resistance,integrins,stemness},
month = {jan},
pages = {1--7},
publisher = {Elsevier Ltd},
title = {{Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance}},
url = {http://linkinghub.elsevier.com/retrieve/pii/S0962892414002165},
year = {2015}
}
@article{Cox2010b,
abstract = {The integrins are a large family of cell adhesion molecules that are essential for the regulation of cell growth and function. The identification of key roles for integrins in a diverse range of diseases, including cancer, infection, thrombosis and autoimmune disorders, has revealed their substantial potential as therapeutic targets. However, so far, pharmacological inhibitors for only three integrins have received marketing approval. This article discusses the structure and function of integrins, their roles in disease and the chequered history of the approved integrin antagonists. Recent advances in the understanding of integrin function, ligand interaction and signalling pathways suggest novel strategies for inhibiting integrin function that could help harness their full potential as therapeutic targets.},
author = {Cox, Dermot and Brennan, Marian and Moran, Niamh},
doi = {10.1038/nrd3266},
file = {:Users/evayap/Library/Application Support/Mendeley Desktop/Downloaded/Cox, Brennan, Moran - 2010 - Integrins as therapeutic targets lessons and opportunities.pdf:pdf},
issn = {1474-1784},
journal = {Nature reviews. Drug discovery},
keywords = {Animals,Drug Delivery Systems,Drug Delivery Systems: methods,Drug Delivery Systems: trends,Humans,Integrins,Integrins: antagonists {\&} inhibitors,Integrins: chemistry,Integrins: physiology,Neoplasms,Neoplasms: drug therapy,Neoplasms: metabolism,Structure-Activity Relationship},
month = {oct},
number = {10},
pages = {804--20},
pmid = {20885411},
publisher = {Nature Publishing Group},
title = {{Integrins as therapeutic targets: lessons and opportunities.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/20885411},
volume = {9},
year = {2010}
}
@article{MacDonald2014b,
abstract = {Medulloblastoma (MB) is the most frequent malignant brain tumor in children. Patients with MB who are classified as having high-risk disease or those with recurrent disease respond poorly to current therapies and have an increased risk of MB-related mortality. Preclinical studies and molecular profiling of MB tumors have revealed upregulation or activation of several key signaling pathways such as the sonic hedgehog and WNT pathways. Although the exact mechanisms underlying MB tumorigenesis remain poorly understood, inhibiting these key pathways with molecularly targeted therapies represents an important approach to improving MB outcomes. Several molecularly targeted therapies are already under clinical investigation in MB patients. We discuss current preclinical and clinical data, as well as data from clinical trials of targeted therapies that are either ongoing or in development for MB.},
author = {MacDonald, Tobey J and Aguilera, Dolly and Castellino, Robert C},
doi = {10.1093/neuonc/not147},
file = {:Users/evayap/Library/Application Support/Mendeley Desktop/Downloaded/MacDonald, Aguilera, Castellino - 2014 - The rationale for targeted therapies in medulloblastoma.pdf:pdf},
issn = {1523-5866},
journal = {Neuro-oncology},
keywords = {Animals,Antineoplastic Agents,Antineoplastic Agents: therapeutic use,Cerebellar Neoplasms,Cerebellar Neoplasms: drug therapy,Cerebellar Neoplasms: metabolism,Humans,Medulloblastoma,Medulloblastoma: drug therapy,Medulloblastoma: metabolism,Molecular Targeted Therapy,Neoplasm Proteins,Neoplasm Proteins: antagonists {\&} inhibitors,Signal Transduction},
month = {jan},
number = {1},
pages = {9--20},
pmid = {24305711},
title = {{The rationale for targeted therapies in medulloblastoma.}},
url = {http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3870836{\&}tool=pmcentrez{\&}rendertype=abstract},
volume = {16},
year = {2014}
}
@article{Gajjar2006d,
abstract = {BACKGROUND: Current treatment for medulloblastoma, which includes postoperative radiotherapy and 1 year of chemotherapy, does not cure many children with high-risk disease. We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma.

METHODS: After resection, patients were classified as having average-risk medulloblastoma ({\textless} or = 1.5 cm2 residual tumour and no metastatic disease) or high-risk medulloblastoma ({\textgreater} 1.5 cm2 residual disease or metastatic disease localised to neuraxis) medulloblastoma. All patients received risk-adapted craniospinal radiotherapy (23.4 Gy for average-risk disease and 36.0-39.6 Gy for high-risk disease) followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy. Patients were assessed regularly for disease status and treatment side-effects. The primary endpoint was 5-year event-free survival; we also measured overall survival. This study is registered with ClinicalTrials.gov, number NCT00003211.

FINDINGS: Of 134 children with medulloblastoma who underwent treatment (86 average-risk, 48 high-risk), 119 (89{\%}) completed the planned protocol. No treatment-related deaths occurred. 5-year overall survival was 85{\%} (95{\%} CI 75-94) in patients in the average-risk group and 70{\%} (54-84) in those in the high-risk group (p=0.04); 5-year event-free survival was 83{\%} (73-93) and 70{\%} (55-85), respectively (p=0.046). For the 116 patients whose histology was reviewed centrally, histological subtype correlated with 5-year event-free survival (p=0.04): 84{\%} (74-95) for classic histology, 77{\%} (49-100) for desmoplastic tumours, and 57{\%} (33-80) for large-cell anaplastic tumours.

INTERPRETATION: Risk-adapted radiotherapy followed by a shortened schedule of dose-intensive chemotherapy can be used to improve the outcome of patients with high-risk medulloblastoma.},
author = {Gajjar, Amar and Chintagumpala, Murali and Ashley, David and Kellie, Stewart and Kun, Larry E and Merchant, Thomas E and Woo, Shaio and Wheeler, Greg and Ahern, Valerie and Krasin, Matthew J and Fouladi, Maryam and Broniscer, Alberto and Krance, Robert and Hale, Gregory a and Stewart, Clinton F and Dauser, Robert and Sanford, Robert a and Fuller, Christine and Lau, Ching and Boyett, James M and Wallace, Dana and Gilbertson, Richard J},
doi = {10.1016/S1470-2045(06)70867-1},
file = {:Users/evayap/Library/Application Support/Mendeley Desktop/Downloaded/Gajjar et al. - 2006 - Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with n.pdf:pdf},
issn = {1470-2045},
journal = {The Lancet. Oncology},
keywords = {Adolescent,Adult,Antineoplastic Agents, Alkylating,Antineoplastic Agents, Alkylating: therapeutic use,Cerebellar Neoplasms,Cerebellar Neoplasms: mortality,Cerebellar Neoplasms: pathology,Cerebellar Neoplasms: therapy,Child,Child, Preschool,Combined Modality Therapy,Cranial Irradiation,Cranial Irradiation: methods,Cyclophosphamide,Cyclophosphamide: therapeutic use,Disease Progression,Dose-Response Relationship, Drug,Female,Follow-Up Studies,Hematopoietic Stem Cell Transplantation,Hematopoietic Stem Cell Transplantation: methods,Humans,Male,Medulloblastoma,Medulloblastoma: mortality,Medulloblastoma: pathology,Medulloblastoma: therapy,Prospective Studies,Risk Factors,Survival Analysis,Survival Rate,Transplantation, Autologous,Treatment Outcome},
month = {oct},
number = {10},
pages = {813--20},
pmid = {17012043},
title = {{Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/17012043},
volume = {7},
year = {2006}
}
@article{Gajjar2014b,
abstract = {Medulloblastoma is a form of brain cancer that mainly arises during infancy and childhood. Our understanding of this disease has transitioned rapidly; what was once thought of as a single disease entity is now known to be a compendium comprising at least four distinct subtypes of tumour (Wnt, sonic hedgehog [SHH], group 3, and group 4 medulloblastomas) that have characteristic molecular signatures, distinctive clinical features, and are associated with different outcomes. Importantly, medulloblastomas occurring in infants (aged up to 3 years) and adults have unique characteristics, which distinguish the disease from that seen in children aged {\textgreater}3 years. Accordingly, modern treatment approaches in medulloblastoma integrate the molecular and clinical features of the disease to enable provision of the most-effective therapies for each patient, and to reduce long-term sequelae. This Review discusses our current knowledge of medulloblastoma. In particular, we present the genetic and histological features, patient demographics, prognosis, and therapeutic options for each the four molecular tumour subtypes that comprise this disease entity. In addition, the unique features of medulloblastoma in infants and in adults, as compared with childhood and/or adolescent forms, are described.},
author = {Gajjar, Amar J and Robinson, Giles W},
doi = {10.1038/nrclinonc.2014.181},
file = {:Users/evayap/Library/Application Support/Mendeley Desktop/Downloaded/Gajjar, Robinson - 2014 - Medulloblastoma-translating discoveries from the bench to the bedside.pdf:pdf},
issn = {1759-4782},
journal = {Nature reviews. Clinical oncology},
month = {dec},
number = {12},
pages = {714--22},
pmid = {25348790},
publisher = {Nature Publishing Group},
title = {{Medulloblastoma-translating discoveries from the bench to the bedside.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/25348790},
volume = {11},
year = {2014}
}
@article{Hazlehurst2003b,
abstract = {The emergence of clinical drug resistance continues to be an obstacle for the successful treatment of cancer. Our current understanding of mechanisms associated with drug resistance has been ascertained by investigating drug-resistant models created by exposing a parental population to increasing concentrations of a cytotoxic. These unicellular drug-resistant models have been critical in elucidating drug-resistant mechanism and in some cases have aided in the identification of drug targets. However, these models do not address resistance mechanisms that contribute to de novo drug resistance. We propose that specific niches within the tumor microenvironment may provide a sanctuary for subpopulations of tumors cells that affords a survival advantage following initial drug exposure and may facilitate the acquisition of acquired drug resistance. More specifically, we propose that the bone marrow microenvironment is a sanctuary for hema-topoietic cancers. This review will focus on the bone marrow microenvironment and its role in conferring resistance to cytotoxics and physiological mediators of cell death.},
author = {Hazlehurst, Lori a and Landowski, Terry H and Dalton, William S},
doi = {10.1038/sj.onc.1206943},
file = {:Users/evayap/Library/Application Support/Mendeley Desktop/Downloaded/Hazlehurst, Landowski, Dalton - 2003 - Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological med.pdf:pdf},
issn = {0950-9232},
journal = {Oncogene},
keywords = {Animals,Antineoplastic Agents,Antineoplastic Agents: pharmacology,Apoptosis,Apoptosis: drug effects,Cell Adhesion,DNA Damage,DNA Damage: drug effects,Drug Resistance, Neoplasm,Humans,Integrins,Integrins: metabolism,Neoplasms,Neoplasms: metabolism,Neoplasms: pathology,Signal Transduction},
month = {oct},
number = {47},
pages = {7396--402},
pmid = {14576847},
title = {{Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/14576847},
volume = {22},
year = {2003}
}
@article{HÃ¸ye2012b,
abstract = {Integrins are heterodimeric transmembrane receptors regulating cell-cell and cell-extracellular matrix interactions. Of the 24 integrin heterodimers identified in humans, $\alpha$9$\beta$1 integrin is one of the least studied. $\alpha$9, together with $\alpha$4, comprise a more recent evolutionary sub-family of integrins that is only found in vertebrates. Since $\alpha$9 was thought to have similar functions as $\alpha$4, due to many shared ligands, it was a rather overlooked integrin until recently, when its importance for survival after birth was highlighted upon investigation of the $\alpha$9 knockout mouse. $\alpha$9$\beta$1 is expressed on a wide variety of cell types, interacts with many ligands for example fibronectin, tenascin-C and ADAM12, and has been shown to have important functions in processes such as cell adhesion and migration, lung development, lymphatic and venous valve development, and in wound healing. This has sparked an interest to investigate $\alpha$9$\beta$1-mediated signaling and its regulation. This review gives an overview of the recent progress in $\alpha$9$\beta$1-mediated biological and pathological processes, and discusses its potential as a target for cancer diagnosis and therapy.},
author = {H{\o}ye, Anette M and Couchman, John R and Wewer, Ulla M and Fukami, Kiyoko and Yoneda, Atsuko},
doi = {10.1016/j.jbior.2012.03.004},
file = {:Users/evayap/Library/Application Support/Mendeley Desktop/Downloaded/H{\o}ye et al. - 2012 - The newcomer in the integrin family integrin $\alpha$9 in biology and cancer.pdf:pdf},
issn = {2212-4934},
journal = {Advances in biological regulation},
keywords = {ADAM Proteins,ADAM Proteins: metabolism,Animals,Cell Adhesion,Cell Adhesion: physiology,Humans,Integrin alpha Chains,Integrin alpha Chains: genetics,Integrin alpha Chains: physiology,Integrin alpha4,Integrin alpha4: physiology,Integrins,Integrins: physiology,Membrane Glycoproteins,Membrane Glycoproteins: metabolism,Mice,Neoplasms,Neoplasms: physiopathology,Signal Transduction,Signal Transduction: physiology,Tenascin,Tenascin: metabolism,Vascular Endothelial Growth Factors,Vascular Endothelial Growth Factors: metabolism,Wound Healing,Wound Healing: physiology},
month = {may},
number = {2},
pages = {326--39},
pmid = {22781746},
publisher = {Elsevier Ltd},
title = {{The newcomer in the integrin family: integrin $\alpha$9 in biology and cancer.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/22781746},
volume = {52},
year = {2012}
}
